Regulatory Story
Company Oxford Biomedica PLC
Headline Director Dealings / Market Share Purchase
Released 12:57 26-Mar-2019
Number 0582U12

RNS Number : 0582U
Oxford Biomedica PLC
26 March 2019




Director Dealings / Market Share Purchase


Oxford, UK - 26 March 2019: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Dr. Lorenzo Tallarigo, Chairman of the Group, has purchased 382 ordinary shares of 50p each ("Ordinary Shares") in the Company on 25 March 2019 on the London Stock Exchange at a price of 695.4p per share as set out below under the market share purchase agreement outlined in the Group's announcement on 15 December 2015.


Under the market share purchase agreement, one-third of Dr. Tallarigo's fees as Chairman, after tax, are to be used to purchase ordinary shares in Oxford Biomedica plc on a monthly basis at the prevailing market price.


Following this purchase Dr. Tallarigo holds 49,120 ordinary shares representing 0.07% of the Company.


The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.



Details of the person discharging material responsibilities/person closely                 associated




 Lorenzo Tallarigo



Reason for the notification






Initial notification /amendment

 Initial notification



Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor




 Oxford Biomedica plc



Legal Entity Identifier




Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



Description of the financial instrument, type of instrument identification code

 Oxford Biomedica plc Ordinary Shares of 50p each






Nature of the transaction

 Purchase of ordinary shares




 GBP - British Pound



Price(s) and volume(s)













Aggregated information

·      Aggregated volume

·      Price

·      Aggregated total









Date of the transaction




Place of the transaction

 London Stock Exchange, Main Market (XLON)




The issued share capital of the Group is 66,129,701 ordinary 50p shares.








For further information, please contact:



Oxford Biomedica plc:

Stuart Paynter, Company Secretary


Tel: +44 (0)1865 783 000



About Oxford Biomedica


Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available at




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.